ValuEngine downgraded shares of Immunomedics (NASDAQ:IMMU) from a buy rating to a hold rating in a report released on Tuesday morning, ValuEngine reports.

Several other brokerages have also recently weighed in on IMMU. BidaskClub cut shares of Immunomedics from a buy rating to a hold rating in a research note on Tuesday, January 14th. Wells Fargo & Co boosted their target price on shares of Immunomedics from $14.00 to $16.00 and gave the company a market perform rating in a research report on Monday, September 30th. HC Wainwright boosted their target price on shares of Immunomedics from $26.00 to $31.00 and gave the company a buy rating in a research report on Friday, December 27th. B. Riley set a $28.00 target price on shares of Immunomedics and gave the company a buy rating in a research report on Monday, September 30th. Finally, Bank of America assumed coverage on shares of Immunomedics in a research report on Friday, December 20th. They issued a buy rating and a $26.00 target price for the company. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Immunomedics presently has a consensus rating of Buy and an average price target of $26.70.

Immunomedics stock traded down $0.72 during midday trading on Tuesday, hitting $18.05. The company’s stock had a trading volume of 19,912 shares, compared to its average volume of 2,063,515. Immunomedics has a 1-year low of $11.59 and a 1-year high of $22.22. The company has a debt-to-equity ratio of 0.30, a current ratio of 6.51 and a quick ratio of 6.51. The company has a 50-day moving average price of $20.14 and a two-hundred day moving average price of $16.64. The company has a market cap of $3.64 billion, a price-to-earnings ratio of -9.74 and a beta of 2.19.

Immunomedics (NASDAQ:IMMU) last issued its quarterly earnings data on Wednesday, October 30th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.09). During the same period last year, the business posted ($0.34) EPS. Sell-side analysts forecast that Immunomedics will post -1.8 EPS for the current year.

Large investors have recently modified their holdings of the company. FTB Advisors Inc. grew its holdings in shares of Immunomedics by 38.0% during the 4th quarter. FTB Advisors Inc. now owns 1,831 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 504 shares during the last quarter. Arden Trust Co lifted its position in shares of Immunomedics by 8.0% in the 4th quarter. Arden Trust Co now owns 10,957 shares of the biopharmaceutical company’s stock worth $232,000 after purchasing an additional 815 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Immunomedics by 11.5% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,598 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 992 shares during the period. SG Americas Securities LLC lifted its position in shares of Immunomedics by 18.0% in the 3rd quarter. SG Americas Securities LLC now owns 8,655 shares of the biopharmaceutical company’s stock worth $115,000 after purchasing an additional 1,319 shares during the period. Finally, Stifel Financial Corp lifted its position in shares of Immunomedics by 3.1% in the 3rd quarter. Stifel Financial Corp now owns 48,062 shares of the biopharmaceutical company’s stock worth $637,000 after purchasing an additional 1,453 shares during the period. Institutional investors own 82.80% of the company’s stock.

About Immunomedics

Immunomedics, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively.

Further Reading: Market Indexes

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Immunomedics (NASDAQ:IMMU)

Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.